Sodium phenylacetate enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice

M Di Benedetto1, Y Kourbali1, A Starzec2, R Vassy2, J Jozefonvicz3, G Perret2, M Crepin1 and M Kraemer1

1UPRES 2360, Équipe d’Oncologie cellulaire et moléculaire Université Paris 13, 74 Rue Marcel Cachin, 93017 Bobigny cedex, France; 2UPRES 2360, Équipe de Pharmacologie, 93017 Bobigny; 3LRM, CNRS, URM 502, Institut Galilée, Université Paris 13 Avenue JB Clément 93340 Villetaneuse, France

Summary Sodium phenylacetate (NaPa) and carboxymethyl benzylamide dextran derivative (CMDB7) are able to inhibit growth of breast tumour cells. In this study, we explored whether the combination of NaPa and CMDB7 may enhance their respective inhibitory effects on the MCF-7ras cell growth in vitro and in vivo. NaPa inhibited MCF-7ras cell proliferation by reducing the DNA replication concomitantly with a recruitment of cells in G0/G1 phase and by inducing apoptosis in a dose- and time-dependent manner. The addition of CMDB7 potentiated the NaPa antiproliferative effect in the manner dependent on the ratio of CMDB7 and NaPa concentrations. In nude mice, CMDB7 (150 mg kg⁻¹) or NaPa (40 mg kg⁻¹) administrated twice a week, for 7 weeks inhibited MCF-7ras xenograft growth by 40% and 60%, respectively. The treatment by both, CMDB7 and NaPa, decreased tumour growth by 83% without any toxicity. To better understand the mechanism of NaPa and CMDB7 action we assessed their effect on mitogenic activity of MCF-7ras conditioned medium (CM) on BALBC/3T3 fibroblasts. CMDB7 added to the CM, inhibited its mitogenic activity whereas NaPa had an anti-mitogenic effect when CM was prepared from MCF-7ras cells pretreated with NaPa. Thus, the antiproliferative effects of NaPa and CMDB7 involve 2 different mechanisms explaining, at least in part, the possible synergism between them. Overall, this study points to the potential use of a combination of dextran derivatives with NaPa to inhibit the breast tumour growth. © 2001 Cancer Research Campaign

Keywords: sodium phenylacetate (NaPa); carboxymethyl benzylamide dextran derivative (CMDB); synergism; MCF-7ras; breast cancer

We recently showed that carboxymethyl benzylamide dextran derivative (in particular CMDB7) inhibits the breast cancer cell proliferation in vitro and in nude mice (Bagheri-Yarmand et al, 1992, 1997, 1998a,b, 1999). This effect in vitro is associated with a decrease in the S-phase cell population and with an accumulation of cells in G1 phase of cell cycle (Bagheri-Yarmand et al, 1992). CMDB7 disrupts the mitotic effect of growth factors by preventing their binding to specific receptors as reported for Fibroblast Growth Factor-2 and -4 (FGF2, FGF4, Bagheri-Yarmand et al, 1998a), Platelet-Derived Growth Factor-BB and Transforming Growth Factor-β1 (PDGF-BB, TGFβ Bagheri-Yarmand et al, 1999b). In vivo, CMDB7 treatment reduces the growth of MCF-7ras (Bagheri-Yarmand et al, 1998b) and FGF4-transfected HBL100 xenografts and decreases the tumour angiogenesis (Bagheri-Yarmand et al, 1998a).

Sodium phenylacetate (NaPa), a physiological metabolite of phenylalanine, is normally found in human plasma at micromolar concentrations. At higher concentrations, NaPa was reported to induce the cytostasis and the reversion of malignant phenotype of different cancer cells in vitro (Samid et al, 1993, 1994, 1997, 2000; Adam et al, 1995). Furthermore, NaPa was described to modulate the synthesis and/or the release of some growth factors (Ferrandina et al, 1997; Thibaut et al, 1998) and to increase, in a synergistic manner, the effect of some molecules affecting the growth factor pathways (Samid et al, 1993; Prasanna et al, 1996). For example, NaPa potentiated the antitumour activity of tamoxifen by increasing apoptosis induction in breast cancer xenografts in nude mice. Finally, NaPa had been used in phase I and II clinical trials on patients with malignant tumours (Thibault et al, 1994; Chang et al, 1999).

In this study, we investigated in vitro and in vivo the efficacy of combined treatment with NaPa and an industrial dextran derivative LS4 (Sterilyo Laboratories) whose composition is similar to CMDB7 one, on breast cancer cell growth. We have used the MCF-7ras cell line obtained by transfection of MCF-7 cells, isolated from pleural metastasis of breast adenocarcinoma, with v-Ha-ras oncogene. The MCF-7ras cells secrete high quantities of TGFα, TGFβ, epidermal growth factor (EGF) and insulin growth factor (IGF) (Albini et al, 1986). This cell line represents an oestrogen-independent cellular model corresponding to some malignant breast tumours (Spandidos and Agnantis, 1984) and it does not require the oestrogen supplementation to induce a high incidence of tumours in nude mice (Sommers et al, 1990). The analysis of CMDB7-NaPa combination effect was performed by the isobole method. Then, we explored the mechanism of action of CMDB7-NaPa combination.

MATERIALS AND METHODS

Compound preparation

NaPa was provided by Seratec (Paris, France). Industrial watersoluble dextran derivative CMDB7 was synthetized by Sterilyo Laboratories (Levallois-Perret, France)
with some modifications of the procedure described by Mauzac and Jozefonvicz (1984) and by Chauvet et al (1995). In brief, CMDBLS4 was prepared by simultaneous carboxymethylation and benzylamidation of dextran T40 in one step. After purification by ultrafiltration and lyophilization, the chemical composition (or degree of substitution, ds) of CMDBLS4 was determined by acidimetric titration and elementary analysis of nitrogen. The dextran, carboxymethyl (CM) and benzylamide (B) was 0, 0.67 and 0.33, respectively. The average molecular weight, calculated considering CMDB subunits was PM$_{\text{CM}}$ + ds$_{\text{CM}}$ × PM$_{\text{CM}}$ + ds$_{\text{B}}$ × PM$_{\text{B}}$ = 264.1 g mol$^{-1}$.

**Cell culture**

The human breast cancer MCF-7ras cells, derived from the pleural effusion MCF-7 cells transfected with v-Ha-ras, were kindly provided by Dr C Sommers (Georgetown University, Washington, DC, USA). BALB/c3T3 fibroblasts were purchased from American Tissue Culture Collection (Rockeville, MA, USA). All cells were routinely grown in DMEM supplemented with i-glutamine 2 mM, penicillin 50 IU ml$^{-1}$, streptomycin 50 µg ml$^{-1}$, and fetal calf serum 10% (FCS) (Life Technologies, Inc, Gaithersburg, MD, USA) at 37°C in a 5% CO$_2$ humidified atmosphere.

**Growth inhibition experiments**

MCF-7ras cell growth was assessed using the MTT-microculture tetrazolium assay (Mosmann, 1983). As previously described, CMDB7 antiproliferative effect is FCS concentration-dependent with an optimum observed in the presence of 1 to 2% of FCS (Bagheri-Yarmand et al, 1992). Briefly, the cells (4 × 10$^4$) were incubated in 2% FCS/DMEM for 24 h and then treated with NaPa or/and CMDBLS4 at different concentrations for 72 h. Then, the drug interaction between NaPa and CMDBLS4 was evaluated by comparison of the dose–response curves of MTT assay for single agents and combined treatment. The characteristics of the combined treatment were then analysed by the isobole method (Berenbaum, 1981) analysing the equation $A_c/A_e + B_c/B_e = D$, where $A_c$ and $B_c$ correspond to concentrations of drugs A and B used in the combined treatment, and $A_e$ and $B_e$ are the concentrations of drugs able to produce the same magnitude of effect if used individually. If D (combination index) < 1, the effect of combination is synergistic, when D = 1 its effect is additive and in the case of D > 1 the combined action is antagonistic. Each experiment was performed in triplicate and the statistical significance (P) of the difference between D obtained and D = 1 was calculated by the Student’s t-test.

**Preparation of conditioned medium (CM)**

MCF-7ras cells (1 × 10$^6$) were treated with or without NaPa 20 mM for 48 h in DMEM supplemented with FCS 2% and washed twice with PBS. To obtain conditioned medium (CM) containing only the growth factors produced by MCF-7ras, the cells were incubated with serum-free DMEM for 24 h at 37°C. This medium (CM) was then harvested and used directly.

**CM experiments**

BALB/c3T3 fibroblasts (5 × 10$^4$) were grown until preconfluence in DMEM supplemented with FCS 10%, washed twice with PBS and growth-arrested by serum starvation for 24 h. Then, 0.75 ml of the CM from MCF-7ras cells, treated or not with NaPa, was added to 0.25 ml of DMEM containing or not the CMDBLS4 or NaPa. After 48 h, the proliferative effects of the CM was measured by counting the fibroblasts using a Coulter counter (Coultronics, Margency, France).

**Cell cycle analysis**

MCF-7ras cells (5 × 10$^4$ ml$^{-1}$) were plated in DMEM supplemented with FCS 2%. After 24 h of culture, NaPa was added for 72 h. Then, the cells were treated with BrdU (Pharmingen, San Diego, CA, USA) for 4 h. The incorporated BrdU was revealed using an anti-BrdU conjugated with fluorescein isothiocyanate (Boehringer Mannheim, Germany). Then, the cells were stained with propidium iodide (PI) (Boehringer) for 10 min and were analysed using a flow cytometer (Coulter Epic Laser, CA, USA).

**Evaluation of cell death**

Trypan blue and propidium iodide (PI) enter into the cells during the ultimate stage of apoptosis or predominantly the first stage of necrosis when damage of the cell membrane has occurred. After the different treatment, the cells were harvested and the cell viability was determined by trypan blue exclusion. Other aliquot of the same sample cells were centrifuged and washed with annexin buffer (Boehringer). To reveal a phosphatidylserine translocation specific to apoptosis stage, the cells were treated with a FITC-labelled annexin V (Boehringer) followed by PI (Boehringer) and finally the cells were analysed using a flow cytometer.

**Xenografts in nude mice**

MCF-7ras cells (5 × 10$^6$) were inoculated s.c. near the right mammary fad pad of 3-week-old athymic nude mice (nu/nu) (Harlan laboratory, Gannat, France). The animals (n = 40) were kept in a temperature-controlled room on a 12h:12h light–dark schedule with food and water ad libitum. This protocol resulted in the development of single s.c. palpable tumours 4 weeks after cell inoculation in 90% of the mice. Then, the animals were arbitrarily placed in control (n = 10) and treated groups (n = 10). NaPa (40 mg kg$^{-1}$), CMDBLS4 (150 mg kg$^{-1}$) or CMDBLS4 /NaPa combination (150/40 mg kg$^{-1}$, respectively) were injected s.c. in 0.1 ml of NaCl 0.9% twice a week for 7 weeks. The control group received s.c. 0.1 ml of NaCl 0.9%. A tumour volume was calculated as previously described (Bagheri-Yarmand et al, 1998a).
Statistical analysis

Multiple statistical comparisons were performed using ANOVA in a multivariable linear model. Some statistical comparisons were conducted using the Mann–Whitney t-test. $P < 0.05$ was considered statistically significant.

RESULTS

Inhibition of MCF-7ras cell growth by NaPa

After 72 h exposure, NaPa induced a dose-dependent inhibition (IC$_{50} = 20$ mM) of MCF-7ras cell growth (Figure 1A). This decline was associated with a similar inhibition of DNA synthesis (Figure 1A) as well as with a decrease in MCF-7ras cell number in S-phase and a major recruitment of cells in the G0/G1 phase (Figure 1B).

NaPa induced the cell death but only at high concentration (40 mM) (Figure 2A). At concentrations ranged from 5 to 30 mM NaPa did not induce apoptotic, necrotic or toxic effects as showed by the negative results of trypan blue exclusion test and annexin V labelling. In the presence of NaPa 40 mM, we observed 40% of cells double labelled with annexin V/PI. Moreover, this result was confirmed using trypan blue exclusion test. The apoptotic effect of NaPa 40 mM on MCF-7ras cells was time-dependent (Figures 2B and 3). No apoptotic or necrotic effects were observed after 24 h of treatment (data not shown). After 48 h of treatment, 2 separate annexin V positive cell populations were observed. The first one represented 10% of total cells and contained annexin V single stained cells being in an early apoptotic phase. The other one included 18% of annexin V/PI double stained cells or trypan blue-stained cells progressing in a later apoptosis or in the early stage of necrosis. After 72 h of treatment, only annexin V/PI double-stained cell population (40%) was found.

Improvement of MCF-7ras cell growth inhibition by CMDB$_{Ls4}$-NaPa combination

As shown in Figure 4, the antiproliferative effect of CMDB$_{Ls4}$ on MCF-7ras cells was potentiated in the presence of NaPa 5 mM. Indeed, CMDB$_{Ls4}$ 18 mM alone was not able to inhibit the MCF-7ras cell growth by more than 38% (IC$_{50}$ not reached), whereas in
the presence of NaPa 5 mM, CMDBLS4 was more potent and reduced the cell growth with an IC50 of 12 mM.

In order to better characterize the inhibition of MCF-7ras cell growth by CMDBLS4-NaPa combination, we evaluated this inhibitory effect for various CMDBLS4 and NaPa concentrations and for their different ratios (CMDBLS4/NaPa) in a range from 0.01 to 8 (Table 1). The inhibition of MCF-7ras cell growth induced by CMDBLS4-NaPa combination was compared to their single respective effect. Only for CMDBLS4/NaPa ratios > 1 the inhibitory effect was potentiated.

For CMDBLS4/NaPa ratio = 5, an additive inhibition (40–50%) was observed after 48 h and 72 h when higher drug concentrations were used (Table 2). A synergistic inhibitory effect was detected for lower concentrations of CMDBLS4 and NaPa. In all cases of combined treatment, an increase in MCF-7ras cell growth inhibition was time-dependent. When used in combination, NaPa and CMDBLS4 are efficient at much lower concentrations than when applied separately to induce the same inhibitory effect. The best combination seems to be 3.7 mM CMDBLS4/0.75 mM NaPa. The different combined treatments were not cytotoxic as determined by a trypan blue exclusion test (data not shown).

Effect of NaPa and CMDBLS4 on MCF-7 ras CM mitogenic activity on fibroblast proliferation

Previous reports indicated that MCF-7 ras cells secreted the growth factors mitogenic for BALBc/3T3 fibroblasts (Bagheri-Yarmand et al, 1998a). We investigated whether CMDBLS4 or NaPa could influence the mitogenic activity of MCF-7ras cell conditioned medium (CM) (Figure 5). CM stimulated BALBc/3T3 fibroblast proliferation 2-fold after 48 h of treatment. The addition of CMDBLS4 18.5 mM abolished the MCF-7ras CM stimulation of
Growth inhibition of breast cancer cells by NaPa and CMDBLS4 combination

Antitumour activity of CMDBLS4-NaPa combination on MCF-7ras cell xenografted into nude mice

We focused our attention on the in vivo effect of CMDBLS4-NaPa combination in a ratio of CMDBLS4/NaPa > 1 (Figure 6). NaPa (40 mg kg⁻¹ twice a week) inhibited by 60% \( (P < 0.05) \) the growth of MCF-7ras tumours after 7 weeks of treatment. No apparent toxicity was reported during mice treatment as their weight remained stable between day 0: 28.4 g ± 1 and day 7: 30 ± 1. CMDBLS4 (150 mg kg⁻¹) delivered alone for 7 weeks, inhibited MCF-7ras tumour growth by 40% \( (P < 0.05) \) after 7 weeks of treatment without toxicity. When NaPa and CMDBLS4 were administered at the same dose but in combination, the tumour growth was inhibited by 83% \( (P \leq 0.001) \) after 7 weeks and no mice toxicity (mice weight at day 0: 28.9 g ± 0.6, day 7: 33.0 ± 0.01) was noticed.

DISCUSSION

Our study demonstrates, for the first time to our knowledge, that NaPa enhances dextran derivative, CMDBLS4, antiproliferative effect on breast cancer MCF-7ras cells in vitro and in vivo. Indeed, NaPa or CMDBLS4, delivered alone for 7 weeks, inhibited MCF-7ras tumour growth by 60% and 40%, respectively, while the CMDBLS4-NaPa combination decreased MCF-7ras tumour growth by 83% without any toxicity. The effectiveness of the NaPa and CMDBLS4 combination could be explained by their distinct mechanisms of action. MCF-7ras breast cancer cells secrete an important amount of mitogenic growth factors such as TGF\( \beta \) and PDGF (Bronzert et al, 1987; Dickson et al, 1987; Knabbe et al, 1987). The mitogenic effects of these growth factors could be reduced by inhibition of their synthesis or/and their action on target cells. In our study, we showed that a treatment of cells with NaPa decreased the mitogenic activity of MCF-7ras conditioned medium on BALBc/3T3 fibroblasts. This could be explained by a modulation of the synthesis and the release of growth factors like TGF\( \beta \) in MCF-7ras breast cancer cells as reported previously by our laboratory (Thibout et al, 1998). Concerning CMDBLS4, we have demonstrated here that when added to CM it inhibited CM mitogenic effect on BALBc/3T3 fibroblasts. This finding argues for CMDBLS4 interactions with growth factors contained in CM. Indeed, previous studies showed that dextran derivative interacted with heparin-binding growth factors like TGF\( \beta \), PDGFBB or FGF-2 and inhibited their mitogenic effect (Bagheri-Yarmand et al, 1998a, b). All our and others’ observations suggest that NaPa...
and CMDBLS4 act on distinct targets involved in the tumour development. NaPa alters the mitogenic growth factor production and rendered the tumour cells quiescent in the G1 phase while CMDBLS4 interacts with MCF-7ras growth factors and inhibits their mitogenic activities.

The additive and synergistic effect in vitro and in vivo was observed when the concentrations of CMDBLS4 were 1 to 8-fold higher than NaPa concentration. If the CMDBLS4/NaPa ratio in vitro is lower than 0.1, the concentrations of CMDBLS4 are probably too low to potentiate the NaPa inhibitory effect although they are efficient when CMDBLS4 is used alone. When the ratio of CMDBLS4 and NaPa concentrations is higher than 5, the inhibitory effect was unchanged suggesting that maximal efficiency of treatment is achieved at ratio 5. Within this same ratio, the combined antiproliferative effect was synergistic when NaPa and CMDBLS4 concentrations were low and it became additive in the case of higher concentrations. This complexity of interaction between 2 drugs may be due to the fact that at different concentrations the drugs could induce various effects. For example, we showed that NaPa at concentration 5 mM, begun to induce G1–S transition arrest, whereas at higher concentration (40 mM), it generated the apoptosis after 48 h of treatment of 10% of cell as revealed by annexin V labelling and after 72 h, the destruction of cell membrane integrity probably due to necrosis or/and later apoptosis as showed by annexin V/Pi labelling. The difficulty to distinguish the apoptotic cells from the necrotic ones may be, in part, explained by the fact that some drugs at high doses can induce new morphological features characteristic of both apoptosis and necrosis chimerically termed aponecrosis as proposed by Formigli et al (2000). MCF-7ras cell apoptosis induced by NaPa was previously described and associated with a reduction of the antiapoptotic Bcl2 gene expression (Adam et al, 1995).

It is noteworthy that NaPa at high concentrations can induce pathological effects (Thibault et al, 1994; Chang et al, 1999) that may involve an induction of cell death as we observed in vitro. The use of combined treatments, reported in this paper, should reduce the dose of NaPa without decreasing a therapeutic efficacy and consequently should limit side effects. Indeed, we observed here an important MCF-7ras xenograft growth cytostatic inhibition (83%) using much lower concentrations of NaPa which are not toxic. Moreover, NaPa does not induce a multi-drug resistance (Adam et al, 1995).

In conclusion, our results clearly indicate the complementary action of NaPa and CMDBLS4 on the autocrine or/and paracrine loops of growth factors to induce, at low doses, a tumour cell cytostatic effect. An important perspective of this study is based on the improvement of the antiproliferative properties of dextran derivatives depending on active subunit substitutions (Bagheri-Yarmard et al, 1992). Currently, we are investigating the antiproliferative effect of a carboxymethylbenzylamide dextran derivative substituted with active phenylacetate subunits.

ACKNOWLEDGEMENTS

The authors thank L. Dahri-Correia and J Correia (LS4 sample) and P Bissière for technical advices. We thank Dr G Palmieri and Dr Frojmoc for language correction. This work was supported by a grant from the ‘Association pour la Recherche sur le Cancer’, ‘Ligue contre le Cancer’, ‘Ministère de l’Education Nationale’ and Sterlino Laboratories.

REFERENCES

Adam L, Crepin M, Savin C and Israel L (1995) Sodium phenylacetate induces growth inhibition and Bcl2 down regulation and apoptosis in MCF-7ras cells in vitro and in nude mice. Cancer Res 55: 5156–5160

Adam L, Crepin M and Israel L (1997) Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras by sodium phenylacetate and tamoxifene combination. Cancer Res 57: 1023–1029

Albini A, Graf J, Kitten GT, Kleinlan HK, Martin GR, Veilllette A and Lippman ME (1986) 17β estradiol regulates and V-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci USA 83: 8182–8186

Bagheri-Yarmard R, Moreere JF, Lefoueneur D, Jozefonvicz J, Israel L and Crepin M (1992) Inhibitory effect of dextran derivatives in vitro on the growth characteristics of premalignant and malignant human mammary epithelial cell lines. Anticancer Res 12: 1641–1646

Bagheri-Yarmard R, Liu JF, Ledoux D, Moreere JF and Crépin M (1997) Inhibition of human breast epithelial HBL 100 cell proliferation by a dextran derivative (CMDB7) with FGFr2 autocrine loop. Biochem Biophys Res Commun 239: 424–428

Bagheri-Yarmard R, Kourbaly Y, Mahibar C, Moreere JF, Martin A, Lu LH, Soria C, Jozefonvicz J and Crepin M (1996a) The supression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumor angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7). Br J Cancer 78: 111–118

Bagheri-Yarmard R, Kourbaly Y, Moreere JF, Jozefonvicz J and Crepin M (1998b) Inhibition of MCF-7ras tumor growth by benzylamide dextran: blockage of the paracrine factor and receptor binding of transforming growth factor β1 and platelet-derived growth factor BB. Cell Growth Differ 9: 497–504

Bagheri-Yarmard R, Kourbaly Y, Ruth AM, Vassy R, Martin A, Jozefonvicz J, Soria C, He L and Crépin M (1999) Carboxymethyl benzylamide dextran blocks angiogenesis of MDA-MB 435 breast carcinoma xenografted in fad pad and its lung metastases in nude mice. Cancer Res 59: 507–510

Benemann KC (1981) Criteria for analysing interaction between biologically active agents. Adv Cancer Res 25: 269–335

Bronzetti P, Pantazis P, Antonioades JH, Kasid A, Davidson N, Dickson RB and Lippman ME (1987) Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci USA 84: 5763–5767

Chang SM, Kuhn JG, Robin HI, Clifford Schold S, Spence AM, Berger MS, Metha MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C and Prados MD (1999) Phase II study of phenylacetate in patients with recurrent malignant glioma, a north American brain tumor consortium. J Clin Oncol 17: 984–990

Chabert F, Champion J, Maiga O, Mauvy S and Jozefonvicz J (1995) Synthesis and structure-anticoagulant property relationships of functionalized dextran: CMDBS. Carbohydrate Polymers 28: 145–152

Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzetti D, Gelman EP and Lippman ME (1987) Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17β estradiol or V-Ha-ras oncogene. Proc Natl Acad Sci USA 84: 837–841

Ferrandina G, Melicher B, Loercher A, Versachgen CF, Kodelka AP, Edwards CL, Scambia G, Kavanagh JJ, Abbruzzese JL and Freedman RS (1997) Growth inhibitory effects of sodium phenylacetate (NSC 30309) on ovarian carcinoma cells in vitro. Cancer Res 57: 4309–4315

Formigli L, Papucci L, Tani A, Schiavone N, Tempestini A, Orlandini GE, Capiscoi C and Orlandini SZ (2000) Aponecrosis: morphological and biochemical exploration of a syncytic process of cell death sharing apoptosis and necrosis. J Cell Physiol 182: 41–49

Knabbe C, Wakefield L, Flanders K, Kasid A, Davidson N, Dickson RB and Lippman ME (1987) Evidence that TGF β1 and platelet-derived growth factor BB. Cell Growth Differ 9: 497–504

Kourbaly Y, Ruth AM, Vassy R, Martin A, Jozefonvicz J, Soria C, He L and Crépin M (1999) Carboxymethyl benzylamide dextran blocks angiogenesis of MDA-MB 435 breast carcinoma xenografted in fad pad and its lung metastases in nude mice. Cancer Res 59: 507–510

Mauruz M and Jozefonvicz J (1994) Anticoagulant activity of dextran derivatives. Part I: Synthesis and characterization. Biomaterials 8: 301–304

Mosmann T (1983) Rapid colorimetric assay for cell growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63

Prasanna P, Thibault A, Liu L and Samid D (1996) Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate and phenylbutyrate. Clin Cancer Res 2: 865–872

Samid D, Shack S and Myers CE (1993) Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by non-toxic pharmacological concentration of phenylacetate. J Clin Invest 91: 2288–2295

Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbridge S, Oldfield EH and Myers CE (1994) Selective activity of phenylacetate against malignant
Glialomas: resemblance to fetal brain damage in phenylketonuria. *Cancer Res* **54**: 891–895
Samid D, Hudgins WR, Shack S, Liu L, Prasanna P and Myers CE (1997) Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. *Adv Exp Med Biol* **400A**: 501–505
Samid D, Wells M, Greene ME, Shen W, Palmer CN and Thibault A (2000) Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. *Clin Cancer Res* **3**: 933–941
Sommers CL, Papageorge A, Wilding G and Gelmann EP (1990) Growth properties and tumorigenesis of MCF-7 cells transfected with isogenic mutants of ras. *Cancer Res* **50**: 67–71
Spandidos DA and Agnantis NJ (1984) Human malignant tumors of the breast as compared to their respective normal tissue have elevated expression of the Harvey ras oncogene. *Anticancer Res* **4**: 269–272
Thibault A, Cooper MR, Figureg WD, Venzan DJ, Sartor OA, Tompkins AC, Weinberg MS, Headlee DJ, Mc Coll Na, Samid D and Myers CE (1994) A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. *Cancer Res* **54**: 1690–1694
Thibout D, Di Benedetto M, Kraemer M, Sainte-Catherine O, Derbin C and Crepin M (1998) Sodium phenylacetate modulates the synthesis of autocrine and paracrine growth factors secreted by breast cancer cell lines. *Anticancer Res* **18**: 2657–2662